AURINIA PHARMACEUTICALS INC's ticker is AUPH and the CUSIP is 05156V102. A total of 190 filers reported holding AURINIA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,846,172 | +15.1% | 1,653,304 | +43.5% | 0.00% | 0.0% |
| Q2 2023 | $11,156,181 | -72.1% | 1,152,498 | -68.4% | 0.00% | -66.7% |
| Q1 2023 | $40,004,800 | +94.0% | 3,650,073 | -23.5% | 0.01% | +80.0% |
| Q4 2022 | $20,618,764 | -28.3% | 4,772,862 | +24.8% | 0.01% | -16.7% |
| Q3 2022 | $28,767,000 | +23.0% | 3,825,316 | +64.4% | 0.01% | +20.0% |
| Q2 2022 | $23,386,000 | -48.8% | 2,326,944 | -36.9% | 0.01% | -44.4% |
| Q1 2022 | $45,687,000 | -51.0% | 3,690,346 | -9.5% | 0.01% | -52.6% |
| Q4 2021 | $93,218,000 | +55.7% | 4,075,993 | +50.7% | 0.02% | +58.3% |
| Q3 2021 | $59,858,000 | +143.9% | 2,704,833 | +42.9% | 0.01% | +140.0% |
| Q2 2021 | $24,538,000 | -31.3% | 1,893,295 | -31.2% | 0.01% | -44.4% |
| Q1 2021 | $35,721,000 | +8.0% | 2,750,993 | +15.1% | 0.01% | +12.5% |
| Q4 2020 | $33,062,000 | -41.9% | 2,390,548 | -38.1% | 0.01% | -52.9% |
| Q3 2020 | $56,862,000 | +194.6% | 3,860,310 | +225.0% | 0.02% | +142.9% |
| Q2 2020 | $19,299,000 | -26.6% | 1,187,632 | -34.4% | 0.01% | -36.4% |
| Q1 2020 | $26,279,000 | -30.6% | 1,811,086 | -3.1% | 0.01% | -31.2% |
| Q4 2019 | $37,849,000 | +1116.2% | 1,868,191 | +220.6% | 0.02% | +1500.0% |
| Q3 2019 | $3,112,000 | +145.2% | 582,711 | +202.2% | 0.00% | – |
| Q2 2019 | $1,269,000 | -8.6% | 192,847 | -9.8% | 0.00% | – |
| Q1 2019 | $1,389,000 | +30.2% | 213,821 | +36.7% | 0.00% | – |
| Q4 2018 | $1,067,000 | -13.5% | 156,458 | -15.7% | 0.00% | – |
| Q3 2018 | $1,233,000 | +235.1% | 185,687 | +184.4% | 0.00% | – |
| Q2 2018 | $368,000 | -41.6% | 65,300 | -46.3% | 0.00% | – |
| Q1 2018 | $630,000 | -45.7% | 121,522 | -52.5% | 0.00% | – |
| Q4 2017 | $1,161,000 | -2.6% | 256,089 | +34.7% | 0.00% | – |
| Q3 2017 | $1,192,000 | -28.9% | 190,100 | -30.5% | 0.00% | -100.0% |
| Q2 2017 | $1,677,000 | -42.4% | 273,670 | -31.0% | 0.00% | -50.0% |
| Q1 2017 | $2,912,000 | +6230.4% | 396,803 | +2504.4% | 0.00% | – |
| Q3 2016 | $46,000 | – | 15,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 230,000 | $993,600 | 1.92% |
| AlphaCentric Advisors LLC | 352,500 | $1,522,800 | 1.50% |
| NEA Management Company, LLC | 3,969,834 | $17,149,683 | 0.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 573,530 | $2,477,650 | 0.76% |
| ARMISTICE CAPITAL, LLC | 5,000,000 | $21,600,000 | 0.38% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 93,658 | $404,603 | 0.27% |
| Artal Group S.A. | 1,000,000 | $4,320 | 0.24% |
| Virtus ETF Advisers LLC | 64,786 | $279,876 | 0.15% |
| TANG CAPITAL MANAGEMENT LLC | 200,000 | $864,000 | 0.13% |
| HighMark Wealth Management LLC | 37,499 | $161,996 | 0.12% |